Format

Send to

Choose Destination
Mol Imaging Biol. 2017 Jun;19(3):348-356. doi: 10.1007/s11307-017-1085-7.

Advancing Drug Discovery and Development Using Molecular Imaging (ADDMI): an Interest Group of the World Molecular Imaging Society and an Inaugural Session on Positron Emission Tomography (PET).

Author information

1
Eisai AiM Institute, 4 Corporate Drive, Andover, MA, USA. shil_patel@eisai.com.
2
Celgene, 86 Morris Avenue, Summit, NJ, USA.
3
inviCRO LLC, 27 Drydock, Boston, MA, USA.

Abstract

Multi-modality molecular imaging techniques have expanded the role of imaging biomarkers in the pharmaceutical industry and are beginning to streamline the drug discovery and development process. The World Molecular Imaging Society (WMIS) serves as a forum for discussing innovative and exploratory multi-modal, interdisciplinary molecular imaging research with a mission of bridging the gap between pathology and in vivo imaging. To formalize the role of the WMIS in pharmaceutical research efforts, members of the society have formed an interest group entitled Advancing Drug Discovery and Development using Molecular Imaging (ADDMI). The ADDMI interest group launched their efforts at the 2016 World Molecular Imaging Congress by hosting a session of invited lectures on translational positron emission tomography (PET) imaging in the central nervous system. This article provides a synopsis of those lectures and frames the role of translational imaging biomarker strategies in the drug discovery and development process.

KEYWORDS:

Drug research and development; Imaging biomarkers; Molecular imaging; Positron emission tomography

PMID:
28417265
DOI:
10.1007/s11307-017-1085-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center